AU2019281018B2 - Combinations of beta-lactam compounds and probenecid and uses thereof - Google Patents

Combinations of beta-lactam compounds and probenecid and uses thereof Download PDF

Info

Publication number
AU2019281018B2
AU2019281018B2 AU2019281018A AU2019281018A AU2019281018B2 AU 2019281018 B2 AU2019281018 B2 AU 2019281018B2 AU 2019281018 A AU2019281018 A AU 2019281018A AU 2019281018 A AU2019281018 A AU 2019281018A AU 2019281018 B2 AU2019281018 B2 AU 2019281018B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
days
acceptable salt
hours
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019281018A
Other languages
English (en)
Other versions
AU2019281018A1 (en
Inventor
Michael Dunne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iterum Therapeutics International Ltd
Original Assignee
Iterum Therapeutics International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterum Therapeutics International Ltd filed Critical Iterum Therapeutics International Ltd
Publication of AU2019281018A1 publication Critical patent/AU2019281018A1/en
Application granted granted Critical
Publication of AU2019281018B2 publication Critical patent/AU2019281018B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019281018A 2018-06-07 2019-06-07 Combinations of beta-lactam compounds and probenecid and uses thereof Active AU2019281018B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862682116P 2018-06-07 2018-06-07
US62/682,116 2018-06-07
US201962804970P 2019-02-13 2019-02-13
US62/804,970 2019-02-13
PCT/EP2019/065016 WO2019234240A1 (en) 2018-06-07 2019-06-07 Combinations of beta-lactam compounds and probenecid and uses thereof

Publications (2)

Publication Number Publication Date
AU2019281018A1 AU2019281018A1 (en) 2020-12-10
AU2019281018B2 true AU2019281018B2 (en) 2025-01-30

Family

ID=67105981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019281018A Active AU2019281018B2 (en) 2018-06-07 2019-06-07 Combinations of beta-lactam compounds and probenecid and uses thereof

Country Status (8)

Country Link
US (3) US11554112B2 (enExample)
EP (1) EP3801486A1 (enExample)
JP (2) JP2021525787A (enExample)
CN (2) CN118903120A (enExample)
AU (1) AU2019281018B2 (enExample)
BR (1) BR112020024498A2 (enExample)
TW (1) TW202005970A (enExample)
WO (1) WO2019234240A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN112739330A (zh) 2019-02-13 2021-04-30 伊泰伦治疗国际有限公司 β-内酰胺化合物和丙磺舒的组合及其用途
AU2021235058A1 (en) * 2020-03-11 2022-09-01 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
WO2021207606A1 (en) * 2020-04-10 2021-10-14 University Of Georgia Research Foundation, Inc. Methods for treatment of coronavirus infections
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN111840236B (zh) * 2020-08-07 2022-09-02 安徽康正康仁药业有限公司 一种注射用美罗培南丙磺舒钠复方冻干制剂
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
CN111821462A (zh) * 2020-08-07 2020-10-27 安徽康正康仁药业有限公司 青霉素类钠盐与丙磺舒钠组成的复方冻干制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031685A1 (en) * 2001-11-19 2005-02-10 Himadri Sen Pharmaceutical composition for controlled release of a beta-lactam antibiotic
CN1813700A (zh) * 2006-03-01 2006-08-09 吴晓辉 丙磺舒钠与青霉素类抗生素组成复方针剂
CN1853724A (zh) * 2004-12-01 2006-11-01 吴晓辉 丙磺舒钠、钾与β－内酰胺类抗生素组成复方针剂及其用途
WO2008001212A2 (en) * 2006-06-28 2008-01-03 Pfizer Products Inc. Penem prodrugs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2520362B1 (fr) * 1982-01-26 1986-04-11 Leo Pharm Prod Ltd Nouveaux composes de type b-lactame, y compris leurs sels formes avec des acides ou des bases acceptables en pharmacie, procedes pour produire ces composes, medicaments les contenant et leur utilisation pour combattre les maladies infectieuses
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
UA59394C2 (uk) 1998-03-27 2003-09-15 Каділа Фармацевтікелс (І.Ей) Лтд. Стійка у фіксованих дозах оральна фармацевтична композиція, що містить антибактеріальний засіб і мікроорганізм одночасно, та спосіб її одержання (варіанти)
ATE266407T1 (de) 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
AU2001227030A1 (en) 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
ES2355950T3 (es) * 2006-06-28 2011-04-01 Pfizer Products Inc. Profármacos de penem.
US20080125408A1 (en) * 2006-11-14 2008-05-29 Pfizer Inc Penem prodrug
CN102711739B (zh) 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
TR201605632A1 (tr) 2016-04-28 2017-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profen ve tramadolün yavaş salinimli kombi̇nasyonlari
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN112739330A (zh) 2019-02-13 2021-04-30 伊泰伦治疗国际有限公司 β-内酰胺化合物和丙磺舒的组合及其用途
AU2021235058A1 (en) 2020-03-11 2022-09-01 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031685A1 (en) * 2001-11-19 2005-02-10 Himadri Sen Pharmaceutical composition for controlled release of a beta-lactam antibiotic
CN1853724A (zh) * 2004-12-01 2006-11-01 吴晓辉 丙磺舒钠、钾与β－内酰胺类抗生素组成复方针剂及其用途
CN1813700A (zh) * 2006-03-01 2006-08-09 吴晓辉 丙磺舒钠与青霉素类抗生素组成复方针剂
WO2008001212A2 (en) * 2006-06-28 2008-01-03 Pfizer Products Inc. Penem prodrugs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
COX VICTORIA C ET AL: "Once-daily cefazolin and probenecid for skin and soft tissue infections", ANNALS OF PHARMACOTHERAPY, HARVEY WHITNEY BOOKS COMPANY, US, vol. 38, no. 3, 29 February 2004, pages 458 - 463, DOI: 10.1345/APH.1D251 *
CUNNINGHAM R F ET AL: "CLINICAL PHARMACOKINETICS OF PROBENECID", CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 6, no. 2, 1 April 1981 (1981-04-01), pages 135 - 151, XP009516127 *
DACEY R G ET AL: "Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives", vol. 6, no. 4, 30 September 1974 (1974-09-30), pages 437 - 441, DOI: 10.1128/AAC.6.4.437 *
FORREST A ET AL: "PK/PD Analysis to Select PF-03709270 (PF) Doses, With & Without Probenecid (P), for Phase 2b Trials", vol. 48, 25 October 2008 (2008-10-25), pages 9, XP009516186, ISSN: 0733-6373 *
GOOTZ T ET AL: "Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester", THE JOURNAL OF ANTIBIOTICS, NATURE PUBLISHING GROUP, vol. 43, no. 4, 1990, pages 422 - 432, DOI: 10.7164/ANTIBIOTICS.43.422 *
M. DUNNE ET AL: "1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with ...", OPEN FORUM INFECTIOUS DISEASES, 2017, S428 - S429 *
R CHANDRA ET AL.: "Pharmacokinetics(PK), safety and tolerability of single oral doses of PF-03709270,with and without co-administration of probenecid introduction" *
R CHANDRA ET AL: "PHARMACOKINETICS (PK), SAFETY AND TOLERABILITY OF SINGLE ORAL DOSES OF PF-03709270, WITH AND WITHOUT CO-ADMINISTRATION OF PROBENECID INTRODUCTION", 89 0.24 2.73 0, 25 October 2008 (2008-10-25), pages 157 - 21 *
SOMA K ET AL: "A1-023 Pharmacokinetics (PK), Safety and Tolerability of Multiple Doses...", ABSTRACTS BOOK, INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS & CHEMOTHERAPY (ICAAC), AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 49, 2009, pages 9 *

Also Published As

Publication number Publication date
CN112739338A (zh) 2021-04-30
BR112020024498A2 (pt) 2021-03-02
US20250127764A1 (en) 2025-04-24
WO2019234240A1 (en) 2019-12-12
US20230218588A1 (en) 2023-07-13
TW202005970A (zh) 2020-02-01
US12109197B2 (en) 2024-10-08
AU2019281018A1 (en) 2020-12-10
US11554112B2 (en) 2023-01-17
JP2024107004A (ja) 2024-08-08
JP2021525787A (ja) 2021-09-27
CN118903120A (zh) 2024-11-08
US20190374516A1 (en) 2019-12-12
EP3801486A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US12109197B2 (en) Combinations of β-lactam compounds and probenecid and uses thereof
US20250120953A1 (en) Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
AU2019429755B2 (en) Combinations of beta-lactam compounds and probenecid and uses thereof
CN118176199A (zh) 三环类硼酸衍生物及其制备方法和应用
ES2290192T3 (es) Derivados de pleuromutilina con actividad antimicrobiana.
CA3129337C (en) Combinations of beta-lactam compounds and probenecid and uses thereof
HK40051087A (en) Combinations of beta-lactam compounds and probenecid and uses thereof
HK40112831A (en) Combinations of beta-lactam compounds and probenecid and uses thereof
EP3075733A1 (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections
CN102153555A (zh) 含有胺基甲酰基杂环的碳青霉烯化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)